SPOTLIGHT: Antisoma gets $25M milestone from Novartis

Antisoma has received a $25 million milestone payment from Novartis, triggered by the recent initiation of a phase III trial of ASA404 in non-small cell lung cancer. Release

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.